Shire Adds EPO-Like Product To Pipeline
This article was originally published in The Pink Sheet Daily
Executive Summary
Deal with Warren gives Shire TPC technology, which would build off Dynepo brand.
You may also be interested in...
Shire’s Elaprase Approved For Hunter Syndrome
The company plans to launch the orphan enzyme replacement therapy within 30 days.
Novartis Institute For Tropical Diseases Could Have TB Drug In Clinic By Late 2007
Singapore-based institute is also looking at dengue fever and malaria, exec says in interview with “The Pink Sheet” DAILY.
Lilly To Settle Additional Zyprexa Liability Cases, Will Pay Up To $500 Million
Lilly will pay up to $500 million to settle the "vast majority" of claims alleging that the company failed to adequately warn patients of risks associated with the atypical antipsychotic Zyprexa (olanzapine), the firm announced Jan. 4